REGISTERED COMPANY NUMBER: 08082786 (England and Wales)

REGISTERED CHARITY NUMBER: 1150234

REPORT OF THE TRUSTEES AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

BRITISH NUCLEAR MEDICINE SOCIETY

Page

Report of the Trustees

1

to

5

Independent Examiner's Report

6

Statement of Financial Activities

7

Balance Sheet

8

Cash Flow Statement

9

Notes to the Cash Flow Statement

10

Notes to the Financial Statements

11

to

16

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to raising the profile of nuclear medicine and to promote the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

Significant activities

In order for the charity to achieve its aim BNMS engages in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.

- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.

- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.

- Leading in the provision of education and training to support the development of nuclear medicine

- Representing the specialty on relevant official bodies and advisory committees

- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.

- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

Our committees

Professional Standards Committee

The Professional Standards Committee advises the Officers and Council of BNMS on the development and implementation of professional standards and audit. They develop, promote, publicise and review guidelines for the delivery of nuclear medicine services and procedures and are also responsible for developing patient information in nuclear medicine.

Scientific and Education Committee

The British Nuclear Medicine Society (BNMS) established the combined Scientific Committee and Education Committee in 2016.

The mandate of the Scientific and Education Committee is to develop an education and scientific programme, nominate invited speakers and the chairs of sessions.

The remit of this committee is to provide resources and encourage the provision of education and training to support Continuing Professional Development/Continuous Medical Education and work towards revalidation. The Education Committee is Multidisciplinary, consisting of Nuclear Medicine Physicians, Clinical Practicer's, Physicists, Nurses and Radiopharmacists.

Research & Innovation Committee

Research & Innovation Committee (RIC) reports to BNMS council and governs BNMS Research Champions network and links to the MRT Research Committee.

The purpose of the RIC is to provide integrated clinical, scientific and operational leadership and management/oversight of delivery of the BNMS Research Strategy.

The roles of the Research & Innovation Committee are to develop and deliver BNMS Research Strategy with aims:

1. To enhance radionuclide research delivery in the United Kingdom leading to service improvement and better care of patients. To accomplish this the BNMS will outline research priority areas highlighting current unmet needs. It will investigate through research sessions and workshops on-line and at face-to-face meetings on how best its multi professional membership can develop projects and achieve funding from the appropriate bodies. The BNMS will facilitate research networks through the BNMS website and offer peer support and review through face-to-face meetings at the BNMS conferences. It will endeavour to contribute to and work with the professional bodies involved in research, the UK Colleges, the charities, and the national and international Nuclear Medicine societies. It will foster links with research partners including the UK PET Network the CRUK Radiation Network, RadNet, the National Cancer Imaging Translational Accelerator (NCITA) and Industry Academic partnership via Industry forum held 2-3 times a year.

2. To build up an evidence base for new radionuclide molecular diagnostic and therapeutic procedures. The BNMS research network group is developing a database of current research in the UK and a data base of available research funding. It is also developing a database to ethically collect data from ongoing research studies.

UK MRT Consortium

The UK molecular radiotherapy consortium is a group comprised of both healthcare professionals and patient advocates who are directly and passionately associated in delivering and caring for patients undergoing molecular radiotherapy based treatments.

The UK MRT Consortium are the first organisation to serve current and future patients who may find the need to receive such types of treatment to help maintain and sustain both quality and duration of life.

By bringing members and fellows of both the British Nuclear Medicine Society and the Royal College of Radiologists together along with patient advocates and nationally recognised charities, we will endeavour to ensure that all parts of the United Kingdom will have equitable access to current and future therapies, raise public awareness of such treatments, design and encourage activity in nationally recognised molecular radiotherapy trials.

Trainee Committee

Aims of BNMS Medical Trainee Committee

Increase awareness of diagnostic and therapeutic Nuclear Medicine amongst doctors-in-training and medical students.

Provide educational content for doctors-in-training and medical students to aid their understanding of working in Nuclear Medicine and the training pathways.

Provide opportunities for doctors-in-training and medical students to engage with the BNMS and improve their application for the specialities/training numbers.

Radiographers Technologists and Nurses

The BNMS Radiographers, Technologists & Nurses' Committee:-

- Represents Radiographers, Technologists & Nurses on the BNMS Council

- Organises sessions at the BNMS Meetings

- Provides advice and opinion on issues affecting all 3 groups

Objectives

- To unite Radiographers, Technologists & Nurses working in Nuclear Medicine into one professional association.

- To encourage professional development and education of these 3 groups by:·

* Co-operating with existing organisations providing education and training

* Supporting and endorsing existing organisations providing education and training.

- To represent the group within the British Nuclear Medicine Society, including participation in organisation of sessions at the Spring and Autumn BNMS meetings.

ACHIEVEMENTS AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held two scientific and educational meetings this year around the UK in addition to online meetings, the results of which are as follows:

Spring

Autumn

Online

Other

2025

2025

Educational

Online Mtgs

Total

£

£

£

£

£

Income

Commercial exhibition income

225,002

29,355

0

1,750

256,107

Annual conference delegate registration fees

150,376

22,912

12,950

4,403

190,641

375,378

52,267

12,950

6,153

446,747

Less: Scientific meeting expenses

261,263

66,959

4,654

2,365

335,235

Surplus

114,115

-14,693

8,296

3,788

111,506

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

FINANCIAL REVIEW

Reserves policy

The trustees aim to maintain free reserves at a level equivalent to at least 18 months of normal operating expenditure in order to protect the continuity of the charity’s activities and provide cover against volatility in conference and event income.

At 31 December 2025, total funds were £517,041 (2024: £479,992), including restricted funds of £14,642 (2024: £14,480), which are not freely available for general purposes.

Unrestricted funds totalled £502,399 (2024: £465,512), of which £2,958 (2024: £1,644) was represented by tangible fixed assets. On that basis, funds freely available for general purposes were approximately £499,441 (2024: £478,348) before taking account of any internal designations.

The trustees consider this level of reserves to be above the minimum target and appropriate in light of the charity’s reliance on event-generated income and the need to support future charitable activities

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, its' articles of association, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

Charity constitution

The affairs of the Society will be governed by a Council of Trustees who will be the officers of the Society and elected members of Council during their period of office.

The Council shall have control of the Society and its property and funds.

Recruitment and appointment of new trustees

New Trustees are elected by the Members or co-opted by the Trustees.

The board of trustees shall be individuals over the age of 18, all of whom must support the Objects, and of whom

at least three shall be registered medical practitioners, two shall be clinical scientists, one shall be a radiopharmacist, and one shall be a technologist or radiographer (clinical paractitioner).

The Council shall ensure that at least one medical position is held by a trainee in the speciality, but if such person whilst on Council is appointed to a consultant position, they shall be eligible to complete their term on Council.

Decision making

Every Trustee has one vote on each issue but, in case of equality of votes, the chairman of the meeting has a second or casting vote.

The Trustees have the following powers in the administration of the Society in their capacity as Trustees:

To appoint (and remove) any person (who may be a Trustee) to act as Secretary in accordance with the Companies Act.

To delegate any of their functions to committees consisting of two or more individuals appointed by them. At least one member of every committee must be a Trustee and all proceedings of committees must be reported promptly to the Trustees.

To make standing orders consistent with the Memorandum, the Articles and the Companies Act to govern proceedings at general meetings.

To make rules consistent with the Memorandum, the Articles and the Companies Act to govern their proceedings and proceedings of committees.

To make regulations consistent with the Memorandum, the Articles and the Companies Act to govern the administration of the Society and the use of its seal (if any).

To establish procedures to assist the resolution of disputes or differences within the Society.

To exercise in their capacity as Trustees any powers of the Society which are not reserved to the Members.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians

11 St Andrews Place

Regents Park

London

NW1 4LE

Trustees

Who are also directors

Mrs J Croasdale (resigned 21 April 2026)

Radiopharmacist

Dr S Redman (appointed 20 April 2026)

Radiologist

Mr C S Kalirai

Clinical Scientist

Mrs S Dizdarevic

Professor

Dr E A Eccles (appointed 21 May 2025)

Doctor

Independent Examiner

E R Grove & Co Limited

Grove House

Coombs Wood Court

Steel Park Road

Halesowen

West Midlands

B62 8BF

Approved by order of the board of trustees on 24 July 2026 and signed on its behalf by:

Mr C S Kalirai - Trustee

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1.	accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or

2.	the accounts do not accord with those records; or

3.	the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

4.

the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas

E R Grove & Co Limited

Grove House

Coombs Wood Court

Steel Park Road

Halesowen

West Midlands

B62 8BF

24 July 2026

2025

2024

Unrestricted

Restricted

Total

Total

fund

fund

funds

funds

Notes

£

£

£

£

INCOME AND ENDOWMENTS FROM

Other trading activities

2

524,282

-

524,282

441,142

Investment income

3

8,046

162

8,208

9,621

Other income

92,016

-

92,016

75,454

Total

624,344

162

624,506

526,217

EXPENDITURE ON

Raising funds

4

587,412

-

587,412

542,381

NET INCOME/(EXPENDITURE)

36,932

162

37,094

(16,164

)

RECONCILIATION OF FUNDS

Total funds brought forward

465,512

14,480

479,992

496,156

TOTAL FUNDS CARRIED FORWARD

502,444

14,642

517,086

479,992

2025

2024

Unrestricted

Restricted

Total

Total

fund

fund

funds

funds

Notes

£

£

£

£

FIXED ASSETS

Tangible assets

10

2,958

-

2,958

1,644

CURRENT ASSETS

Debtors

11

283,339

-

283,339

243,023

Cash at bank

421,366

14,642

436,008

420,001

704,705

14,642

719,347

663,024

CREDITORS

Amounts falling due within one year

12

(205,219

)

-

(205,219

)

(184,676

)

NET CURRENT ASSETS

499,486

14,642

514,128

478,348

TOTAL ASSETS LESS CURRENT LIABILITIES

502,444

14,642

517,086

479,992

NET ASSETS

502,444

14,642

517,086

479,992

FUNDS

13

Unrestricted funds

502,444

465,512

Restricted funds

14,642

14,480

TOTAL FUNDS

517,086

479,992

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

(a)	ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 24 July 2026 and were signed on its behalf by:

Mr C S Kalirai - Trustee

Cash flows from operating activities

Cash generated from operations

1

9,914

(22,766

)

Net cash provided by/(used in) operating activities

9,914

(22,766

)

Cash flows from investing activities

Purchase of tangible fixed assets

(2,115

)

1

Interest received

8,208

9,621

Net cash provided by investing activities

6,093

9,622

Change in cash and cash equivalents in the reporting period

16,007

(13,144

)

Cash and cash equivalents at the beginning of the reporting period

420,001

433,145

Cash and cash equivalents at the end of the reporting period

436,008

420,001

1.	RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES

2025

2024

£

£

Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)

37,094

(16,164

)

Adjustments for:

Depreciation charges

801

770

Interest received

(8,208

)

(9,621

)

Increase in debtors

(40,316

)

(74,498

)

Increase in creditors

20,543

76,747

Net cash provided by/(used in) operations

9,914

(22,766

)

2.	ANALYSIS OF CHANGES IN NET FUNDS

At 1.1.25

Cash flow

At 31.12.25

£

£

£

Net cash

Cash at bank

420,001

16,007

436,008

420,001

16,007

436,008

Total

420,001

16,007

436,008

1.	ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expenses are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings

-

15% on reducing balance

Computer equipment

-

33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees In furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2.	OTHER TRADING ACTIVITIES

2025

2024

£

£

Commercial exhibition income

256,106

225,718

Annual conference delegate registration fees

190,641

135,015

Commission received

448

1,288

Royalties received

74,000

75,835

Other project income

3,087

3,286

524,282

441,142

3.	INVESTMENT INCOME

2025

2024

£

£

Deposit account interest

7,987

9,621

Other interest received

221

-

8,208

9,621

4.	RAISING FUNDS

Raising donations and legacies

2025

2024

£

£

Support costs

117,734

121,255

Other trading activities

2025

2024

£

£

Purchases

364,068

300,138

Awards and prizes

4,186

2,748

Journal subscriptions

44,723

74,029

Support costs

56,701

44,211

469,678

421,126

Aggregate amounts

587,412

542,381

5.	SUPPORT COSTS

Governance

Management

Finance

Other

costs

Totals

£

£

£

£

£

Raising donations and legacies

117,494

-

-

240

117,734

Other trading activities

48,152

2,468

801

5,280

56,701

165,646

2,468

801

5,520

174,435

6.	NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

2025

2024

£

£

Depreciation - owned assets

801

771

7.	TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2025 nor for the year ended 31 December 2024.

Trustees' expenses

Payments totalling £2,118 (2024: £2,558) were made to trustees to reimburse travel costs to conferences and council meetings.

8.	STAFF COSTS

2025

2024

£

£

Wages and salaries

113,400

117,999

Other pension costs

4,094

3,016

117,494

121,015

The average monthly number of employees during the year was as follows:

2025

2024

Administrative

3

3

No employees received emoluments in excess of £60,000.

9.	COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

Unrestricted

Restricted

Total

fund

fund

funds

£

£

£

INCOME AND ENDOWMENTS FROM

Other trading activities

441,142

-

441,142

Investment income

9,414

207

9,621

Other income

75,454

-

75,454

Total

526,010

207

526,217

EXPENDITURE ON

Raising funds

542,381

-

542,381

NET INCOME/(EXPENDITURE)

(16,371

)

207

(16,164

)

RECONCILIATION OF FUNDS

Total funds brought forward

481,883

14,273

496,156

TOTAL FUNDS CARRIED FORWARD

465,512

14,480

479,992

10.	TANGIBLE FIXED ASSETS

Fixtures

and

Computer

fittings

equipment

Totals

£

£

£

COST

At 1 January 2025

905

30,534

31,439

Additions

-

2,115

2,115

At 31 December 2025

905

32,649

33,554

DEPRECIATION

At 1 January 2025

746

29,049

29,795

Charge for year

24

777

801

At 31 December 2025

770

29,826

30,596

NET BOOK VALUE

At 31 December 2025

135

2,823

2,958

At 31 December 2024

159

1,485

1,644

11.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade debtors

78,439

76,022

Other debtors

124,913

73,955

VAT

-

10,541

Prepayments and accrued income

79,987

82,505

283,339

243,023

12.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade creditors

82,660

59,558

Social security and other taxes

2,354

2,539

VAT

6,574

-

Other creditors

108,646

116,877

Accrued expenses

4,985

5,702

205,219

184,676

13.	MOVEMENT IN FUNDS

Net

movement

At

At 1.1.25

in funds

31.12.25

£

£

£

Unrestricted funds

General fund

465,512

36,932

502,444

Restricted funds

Ros Breen Fund

14,480

162

14,642

TOTAL FUNDS

479,992

37,094

517,086